GPBAR1 and atherosclerosis: Preclinical studies with the synthetic TGR5 agonist 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) now also indicate a potential role of TGR5 in the prevention of atherosclerosis.